Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Stock Short Interest Rises 229.2%

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 9,890 shares, an increase of 229.2% from the October 15th total of 3,004 shares. Based on an average trading volume of 25,967 shares, the short-interest ratio is presently 0.4 days. Approximately 0.0% of the company’s shares are short sold.

Emmaus Life Sciences Price Performance

Emmaus Life Sciences stock opened at $0.01 on Friday. The stock’s 50-day moving average is $0.05 and its 200-day moving average is $0.02. The company has a market cap of $1.05 million, a price-to-earnings ratio of -0.17 and a beta of 11.25. Emmaus Life Sciences has a 12 month low of $0.01 and a 12 month high of $0.09.

Emmaus Life Sciences (OTCMKTS:EMMA) last released its quarterly earnings data on Friday, August 14th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $6.32 million during the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and debilitating diseases. The company’s best-known product is Endari, an oral powder formulation of L-glutamine approved in the United States to reduce the frequency of acute complications associated with sickle cell disease in adults and children aged five and older. Emmaus has focused its research and development activities on therapies for diseases with significant unmet medical needs, including hematological and other rare disorders.